NO986173L - FremgangsmÕte for aktivering av dendrittceller - Google Patents
FremgangsmÕte for aktivering av dendrittcellerInfo
- Publication number
- NO986173L NO986173L NO986173A NO986173A NO986173L NO 986173 L NO986173 L NO 986173L NO 986173 A NO986173 A NO 986173A NO 986173 A NO986173 A NO 986173A NO 986173 L NO986173 L NO 986173L
- Authority
- NO
- Norway
- Prior art keywords
- dendritic cells
- procedure
- antigen
- activating dendritic
- cells
- Prior art date
Links
- 210000004443 dendritic cell Anatomy 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 2
- 230000003213 activating effect Effects 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4648—Bacterial antigens
- A61K39/46482—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/52—CD40, CD40-ligand (CD154)
Abstract
Antigenuttrykkende, aktiverte dendrittceller. Slike dendrittceller anvendes for å presentere tumor-, virus- eller bakterieantigener for T- celler, og kan være anvendbare for vaksinasjon. Andre cytokiner kan anvendes i separat, sekvensiell eller samtidig kombinasjon med de aktiverte, antigenpulserte dendrittceller. Også omfattet er fremgangsmåter for stimulering av en immunrespons ved anvendelse av de antigenuttrykkende, aktiverte dendrittceller.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67776296A | 1996-07-10 | 1996-07-10 | |
US08/763,995 US6017527A (en) | 1996-07-10 | 1996-12-12 | Activated dendritic cells and methods for their activation |
PCT/US1997/011956 WO1998001538A1 (en) | 1996-07-10 | 1997-07-09 | Method of activating dendritic cells |
Publications (2)
Publication Number | Publication Date |
---|---|
NO986173D0 NO986173D0 (no) | 1998-12-29 |
NO986173L true NO986173L (no) | 1999-03-10 |
Family
ID=27101890
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO986173A NO986173L (no) | 1996-07-10 | 1998-12-29 | FremgangsmÕte for aktivering av dendrittceller |
Country Status (10)
Country | Link |
---|---|
US (1) | US6497876B1 (no) |
EP (1) | EP0961824A4 (no) |
JP (2) | JP2002514047A (no) |
KR (1) | KR20000022445A (no) |
AU (1) | AU705647B2 (no) |
CA (1) | CA2259140C (no) |
IL (1) | IL127912A0 (no) |
NO (1) | NO986173L (no) |
NZ (1) | NZ333607A (no) |
WO (1) | WO1998001538A1 (no) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20020034517A1 (en) * | 1995-10-04 | 2002-03-21 | Kenneth Brasel | Dendritic cell stimulatory factor |
US7361330B2 (en) * | 1995-10-04 | 2008-04-22 | Immunex Corporation | Methods of using flt3-ligand in the treatment of fibrosarcoma |
US20060002949A1 (en) | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
US5962318A (en) * | 1996-11-15 | 1999-10-05 | St. Jude Children's Research Hospital | Cytotoxic T lymphocyte-mediated immunotherapy |
WO1999012553A1 (en) * | 1997-09-08 | 1999-03-18 | Idec Pharmaceuticals Corporation | Methods for producing human antibodies in scid mice using dendritic cells |
US7402307B2 (en) | 1998-03-31 | 2008-07-22 | Geron Corporation | Method for identifying and killing cancer cells |
WO1999050392A1 (en) | 1998-03-31 | 1999-10-07 | Geron Corporation | Methods and compositions for eliciting an immune response to a telomerase antigen |
EP1733735B1 (en) | 1998-05-22 | 2017-03-22 | Ottawa Hospital Research Institute | Methods and products for inducing mucosal immunity |
AU2215700A (en) * | 1998-12-29 | 2000-07-31 | University Of Vermont And State Agricultural College, The | Use of cd40 engagement to alter t cell receptor usage |
EP1185627A2 (en) * | 1999-06-01 | 2002-03-13 | Cornell Research Foundation, Inc. | Activation of dendritic cells to enhance immunity |
KR100363587B1 (ko) * | 1999-11-12 | 2002-12-06 | 이시우 | 대식세포와 종양세포의 융합에 의한 항종양 세포성 치료제 |
WO2001056603A1 (en) * | 2000-02-01 | 2001-08-09 | Tanox, Inc. | Cd40-binding apc-activating molecules |
ES2254408T4 (es) * | 2000-04-25 | 2007-10-01 | Immunex Corporation | Procedimiento de tratamiento de tumores usando terapia fotodinamica. |
AU2002258379A1 (en) * | 2000-10-24 | 2002-09-19 | Whitehead Institute For Biomedical Research | Response of dendritic cells to a diverse set of pathogens |
US20040247563A1 (en) * | 2000-11-02 | 2004-12-09 | Lynch David H. | Method of enhancing lymphocyte-mediated immune responses |
CA2388441A1 (en) * | 2002-06-10 | 2003-12-10 | Wei-Ping Min | Immunomodulation using rna interference |
JP2006506072A (ja) | 2002-11-12 | 2006-02-23 | デイッセロース,アルバート,ビー | アデノウイルスベクターワクチン |
EP1592441B1 (en) * | 2003-02-06 | 2012-04-11 | Aduro Biotech | Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof |
CA2515298C (en) * | 2003-02-06 | 2014-04-08 | Cerus Corporation | Modified free-living microbes, vaccine compositions and methods of use thereof |
US7695725B2 (en) * | 2003-02-06 | 2010-04-13 | Aduro Biotech | Modified free-living microbes, vaccine compositions and methods of use thereof |
EP2557164A1 (en) | 2003-02-18 | 2013-02-13 | Kevin M. Slawin | Induced activation in dendritic cells |
US8246959B1 (en) | 2003-08-01 | 2012-08-21 | University Of Washington | Dendritic cell-associated lectin-like molecules, compositions and methods of use |
JP2007535304A (ja) | 2003-11-24 | 2007-12-06 | シドニー キンメル キャンサー センター | ムチン抗原ワクチン |
US8828957B2 (en) * | 2003-12-11 | 2014-09-09 | Microvax, Llc | Methods for generating immunity to antigen |
US7999071B2 (en) | 2003-12-12 | 2011-08-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human cytotoxic T-lymphoctye epitope and its agonist eptiope from the non-variable number of tandem repeat sequence of MUC-1 |
US7842289B2 (en) * | 2003-12-24 | 2010-11-30 | Aduro Biotech | Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof |
DE602005025005D1 (de) | 2004-10-07 | 2011-01-05 | Argos Therapeutics Inc | Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung |
US8513008B2 (en) | 2004-10-07 | 2013-08-20 | Argos Therapeutics, Inc. | Mature dendritic cell compositions and methods for culturing same |
KR20170086700A (ko) | 2005-04-08 | 2017-07-26 | 아르고스 쎄라퓨틱스 인코포레이티드 | 수지상 세포 조성물 및 방법 |
WO2007109583A2 (en) | 2006-03-17 | 2007-09-27 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject |
WO2007116409A2 (en) | 2006-04-11 | 2007-10-18 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Improved vaccines comprising multimeric hsp60 peptide carriers |
MX2008013993A (es) * | 2006-05-03 | 2009-05-11 | Univ Colorado | Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular. |
WO2008049113A2 (en) | 2006-10-19 | 2008-04-24 | Baylor College Of Medicine | Generating an immune response by inducing cd40 and pattern recognition receptors |
AR060424A1 (es) * | 2007-04-11 | 2008-06-18 | Consejo Nac Invest Cient Tec | Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento |
EP2155860B1 (en) | 2007-05-03 | 2014-08-27 | The Brigham and Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
US8574567B2 (en) * | 2007-05-03 | 2013-11-05 | The Brigham And Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
JP5227317B2 (ja) | 2007-05-17 | 2013-07-03 | ディナベック株式会社 | 樹状細胞の製造方法 |
ES2840750T3 (es) * | 2008-09-22 | 2021-07-07 | Baylor College Medicine | Métodos y composiciones para generar una respuesta inmune induciendo CD40 y adaptadores del receptor de reconocimiento de patrones |
US8628762B2 (en) | 2008-12-10 | 2014-01-14 | Icahn School Of Medicine At Mount Sinai | T-helper cell type 17 lineage-specific adjuvants, compositions and methods |
US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
US9434935B2 (en) | 2013-03-10 | 2016-09-06 | Bellicum Pharmaceuticals, Inc. | Modified caspase polypeptides and uses thereof |
AU2014236726A1 (en) | 2013-03-14 | 2015-09-17 | Bellicum Pharmaceuticals, Inc. | Methods for controlling T cell proliferation |
JP6467406B2 (ja) | 2013-06-05 | 2019-02-13 | ベリカム ファーマシューティカルズ, インコーポレイテッド | カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法 |
EP3104866A4 (en) | 2014-02-14 | 2017-08-02 | Bellicum Pharmaceuticals, Inc. | Methods for activating t cells using an inducible chimeric polypeptide |
US10888608B2 (en) | 2014-09-02 | 2021-01-12 | Bellicum Pharmaceuticals, Inc. | Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides |
JP6718444B2 (ja) | 2014-11-03 | 2020-07-08 | アカデミッシュ ザイケンホイス レイデン (エイチ.オー.ディー.エヌ. エルユーエムシー) | Bob1に対して指向されるT細胞レセプターおよびその使用 |
WO2017181163A2 (en) | 2016-04-16 | 2017-10-19 | Oncocyte Corporation | Methods and compositions for detection and diagnosis of breast cancer |
WO2018208849A1 (en) | 2017-05-09 | 2018-11-15 | Bellicum Pharmaceuticals, Inc. | Methods to augment or alter signal transduction |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE239790T1 (de) * | 1991-10-25 | 2003-05-15 | Immunex Corp | Antikörper gegen cd40-l |
US5962406A (en) * | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
EP0633929B1 (en) * | 1992-04-01 | 2004-03-03 | The Rockefeller University | METHOD FOR $i(IN VITRO) PROLIFERATION OF DENDRITIC CELL PRECURSORS AND THEIR USE TO PRODUCE IMMUNOGENS |
US5540926A (en) * | 1992-09-04 | 1996-07-30 | Bristol-Myers Squibb Company | Soluble and its use in B cell stimulation |
US5633234A (en) * | 1993-01-22 | 1997-05-27 | The Johns Hopkins University | Lysosomal targeting of immunogens |
IT1264516B1 (it) * | 1993-05-31 | 1996-09-24 | Biotop Sas Di Rita Cassarin | Cellule dendritiche immortalizzate |
US5525708A (en) * | 1994-03-28 | 1996-06-11 | Cytomed, Inc. | Covalent dimer of kit ligand |
IL122174A (en) * | 1995-06-07 | 2004-07-25 | Immunex Corp | DNA encoding the CD40L mutine and CD40L polypeptide encoded by the above DNA |
CN1172718C (zh) * | 1995-10-04 | 2004-10-27 | 依默耐克斯有限公司 | 树突状细胞刺激因子 |
US6080409A (en) * | 1995-12-28 | 2000-06-27 | Dendreon Corporation | Immunostimulatory method |
-
1997
- 1997-07-09 EP EP97933349A patent/EP0961824A4/en not_active Withdrawn
- 1997-07-09 IL IL12791297A patent/IL127912A0/xx active IP Right Grant
- 1997-07-09 WO PCT/US1997/011956 patent/WO1998001538A1/en not_active Application Discontinuation
- 1997-07-09 JP JP50534998A patent/JP2002514047A/ja not_active Withdrawn
- 1997-07-09 KR KR1019980710878A patent/KR20000022445A/ko not_active Application Discontinuation
- 1997-07-09 CA CA002259140A patent/CA2259140C/en not_active Expired - Fee Related
- 1997-07-09 AU AU36554/97A patent/AU705647B2/en not_active Ceased
- 1997-07-09 NZ NZ333607A patent/NZ333607A/xx unknown
-
1998
- 1998-12-29 NO NO986173A patent/NO986173L/no not_active Application Discontinuation
-
1999
- 1999-10-29 US US09/430,448 patent/US6497876B1/en not_active Expired - Fee Related
-
2007
- 2007-12-19 JP JP2007327480A patent/JP2008119004A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU3655497A (en) | 1998-02-02 |
CA2259140C (en) | 2008-09-30 |
JP2008119004A (ja) | 2008-05-29 |
NZ333607A (en) | 2000-08-25 |
EP0961824A4 (en) | 2003-01-29 |
IL127912A0 (en) | 1999-11-30 |
NO986173D0 (no) | 1998-12-29 |
AU705647B2 (en) | 1999-05-27 |
CA2259140A1 (en) | 1998-01-15 |
EP0961824A1 (en) | 1999-12-08 |
US6497876B1 (en) | 2002-12-24 |
JP2002514047A (ja) | 2002-05-14 |
KR20000022445A (ko) | 2000-04-25 |
WO1998001538A1 (en) | 1998-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO986173L (no) | FremgangsmÕte for aktivering av dendrittceller | |
LV12085A (lv) | Dendritiskas sunas stimulejosais faktors | |
WO1998033527A3 (en) | Cancer immunotherapy with semi-allogeneic cells | |
AU2953895A (en) | Multi-stage cascade boosting vaccine | |
EP2377548A3 (en) | Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy | |
GR3036951T3 (en) | Cells with multiple altered epitopes on a surface antigen for use in transplantation | |
DK1225870T3 (da) | Sammensætning og fremgangsmåde til cancerantigenimmunterapi | |
CA2033640A1 (en) | Vaccines against cancer and infectious diseases | |
WO2002036141A3 (en) | Method of enhancing lymphocyte-mediated immune responses | |
WO1999003976A3 (en) | Method of treating leukocytes, leukocyte compositions and methods of use thereof | |
DE69131200D1 (en) | Herpes simplex virus vp16 impfstoffe | |
NZ505834A (en) | Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use | |
WO2000000588A3 (en) | Porcine spinal cord cells and their use in spinal cord repair | |
DK0687300T3 (da) | LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation | |
DE60130634D1 (de) | Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden | |
WO2002015915A3 (en) | Method for inducing an anti-tumor and anti-cachexia immune response in mammals | |
WO2002043651A3 (en) | Methods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease | |
AU6953296A (en) | Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation | |
WO2002066053A3 (en) | Method of treating or preventing disease characterized by cryptococcus neoformans infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |